Which statement best describes the role of P2Y12 inhibitors in STEMI management with PCI?

Which statement best describes the role of P2Y12 inhibitors in STEMI management with PCI?

• A. They provide antiplatelet effect essential with PCI
• B. They act as anticoagulants
• C. They are thrombolytics
• D. They reverse heparin

Answer: (A)

P2Y12 inhibitors provide essential antiplatelet protection during PCI in STEMI. They block the ADP receptor on platelets (P2Y12), preventing platelet activation and aggregation that can lead to thrombus formation on a newly placed stent. This antiplatelet effect is crucial because PCI introduces a surface and flow conditions that raise the risk of clotting, so dual antiplatelet therapy—typically aspirin plus a P2Y12 inhibitor—significantly reduces the chance of stent thrombosis and recurrent ischemia. Different agents (like clopidogrel, prasugrel, and ticagrelor) are used, chosen for their onset and potency to achieve rapid, reliable platelet inhibition, especially important in the acute STEMI setting. They are not anticoagulants, which inhibit the coagulation cascade; they are not thrombolytics, which dissolve clots; and they do not reverse heparin—reversal of heparin, if needed, is a separate consideration.

P2Y12 inhibitors provide essential antiplatelet protection during PCI in STEMI. They block the ADP receptor on platelets (P2Y12), preventing platelet activation and aggregation that can lead to thrombus formation on a newly placed stent. This antiplatelet effect is crucial because PCI introduces a surface and flow conditions that raise the risk of clotting, so dual antiplatelet therapy—typically aspirin plus a P2Y12 inhibitor—significantly reduces the chance of stent thrombosis and recurrent ischemia. Different agents (like clopidogrel, prasugrel, and ticagrelor) are used, chosen for their onset and potency to achieve rapid, reliable platelet inhibition, especially important in the acute STEMI setting. They are not anticoagulants, which inhibit the coagulation cascade; they are not thrombolytics, which dissolve clots; and they do not reverse heparin—reversal of heparin, if needed, is a separate consideration.